Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Provider evaluation A medical professional will review your intake and determine whats right for you
Lilly PACKAGE LABEL - Zepbound Multi-Dose Vial - 10 mg/0.6 mL Dose (40 mg/2.4 mL [16.7 mg/mL]) Rx Only NDC 0002-6304-11 Zepbound (tirzepatide) injection 40 mg/2.4 mL (16.7 mg/mL) ATTENTION: Contains 4 doses of 10 mg/0.6 mL 2.4 mL MULTI-DOSE VIAL For Subcutaneous Use Needles and Syringes are not included Dispense enclosed Medication Guide to each patient
Its recommended to seek medical advice if experiencing the following or if these issues persist or worsen: swelling sensation in the body redness and pain at the injection site temporary itching of the skin mild diarrhea There may also be a risk of: congestive heart failure anaphylaxis polycythemia vera, which is a type of blood cancer peripheral vascular thrombosis, which involves blood clots pulmonary edema If experiencing difficulty breathing, swelling, and hives, patients must seek emergency medical help
AOD-9604 works in the body on adipose tissue, also known as body fat tissue
This is among the highest-risk research peptides from an evidence-to-risk standpoint
PMC (2019) Subcutaneous drug delivery: pharmacologic considerations and techniques American College of Cardiology (2025) REDEFINE 1 and REDEFINE 2 journal scan summary The Lancet (2023) Efficacy and safety of CagriSema in type 2 diabetes: phase 2 trial (Frias et al.) PMC (2024) Efficacy and safety of cagrilintide and CagriSema: systematic review and metaanalysis Pure Lab Peptides Cagrilintide (10 mg) product page (quality and batch documentation) Related research, protocols, and guides Explore the available research context, protocol variants or comparisons, and practical guides
